Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018224536) PARP INHIBITORS FOR USE IN TREATING CANCER
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/224536 International Application No.: PCT/EP2018/064873
Publication Date: 13.12.2018 International Filing Date: 06.06.2018
IPC:
A61K 31/5025 (2006.01) ,A61K 45/06 (2006.01) ,A61P 35/00 (2006.01) ,A61P 35/02 (2006.01) ,G01N 33/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
50
Pyridazines; Hydrogenated pyridazines
5025
ortho- or peri-condensed with heterocyclic ring systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
02
specific for leukemia
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
Applicants:
THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL [GB/GB]; 123 Old Brompton Road London Greater London SW7 3RP, GB
BREAST CANCER NOW [GB/GB]; 5th Floor Ibex House 42-47 Minories London Greater London EC3N 1DY, GB
Inventors:
NATRAJAN, Rachael; GB
LORD, Christopher James; GB
Agent:
KIDDLE, Simon; GB
ADDISS, John; GB
ANDREWS, Robert; GB
BAILEY, Sam; GB
BREARLEY, Sarah; GB
BURNS, Alexander; GB
CARLISLE, Julie; GB
CASLEY, Christopher; GB
CLEGG, Richard; GB
CRIPPS, Joanna; GB
DALE, Elizabeth; GB
DENISON, Christopher; GB
DUNNE, Paul; GB
FORREST, Graham; GB
FURNIVAL, Tom; GB
GILL, Stephen; GB
GRAHAM, Emma; GB
GREEN, Katherine; GB
GREGORY, Adam; GB
HARRISON, Susan; GB
HAYES, Emily; GB
HODSDON, Stephen; GB
JOHNSON, Richard; GB
JONES, Rachel; GB
KEIRSTEAD, Tanis; GB
KREMER, Simon; GB
LEACH, James; GB
LENTHALL, Joseph; GB
LYONS, June; GB
MACIVER, Eleanor; GB
MCGUINN, Callum; GB
MOELLER, Christoph; GB
MOORE, Graeme; GB
NAYLOR, Matthew; GB
OXLEY, Rachel; GB
PARRY, Simon; GB
SALISBURY, Frances; GB
SMITH, Matthew; GB
STONER, Patrick; GB
SUTCLIFFE, Nicholas; GB
THORNTON, Dan; GB
TOLLERVEY, Rebecca; GB
WALTON, Seán; GB
WARD, Eliot; GB
WATSON, Robert; GB
WEBSTER, Jeremy; GB
WESCOTT, Rhiannon; GB
WILLS, Jonathan; GB
WYTENBURG, Wilhelmus; GB
Priority Data:
1709076.207.06.2017GB
Title (EN) PARP INHIBITORS FOR USE IN TREATING CANCER
(FR) INHIBITEURS DE PARP DESTINÉS À ÊTRE UTILISÉS POUR LE TRAITEMENT DU CANCER
Abstract:
(EN) The use of poly ADP ribose polymerase (PARP) inhibitors the treatment of cancer which is mutated or deficient in the SF3B gene is described based on findings indicating that mutations in SF3B1aretherapeutically tractable in cancers using PARP inhibitors and show an impaired response to DNA damage.
(FR) La présente invention concerne l'utilisation d'inhibiteurs de poly(ADP-ribose) polymérase (PARP) dans le traitement d'un cancer qui est muté ou déficient dans le gène SF3B sur la base de résultats indiquant que des mutations dans SF3B1 peuvent être thérapeutiquement traitées dans des cancers au moyen d'inhibiteurs de PARP et présentent une réponse altérée à une lésion d'ADN.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)